Enasidenib Mesylate Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg
Reference Brands: Idhifa (USA)
Category:
Oncology Cancer Care
Enasidenib Mesylate is available in Tablets
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Enasidenib Mesylate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Enasidenib Mesylate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Enasidenib mesylate is a targeted anticancer therapy used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who carry a specific mutation in the isocitrate dehydrogenase-2 (IDH2) gene. It is prescribed when the disease has returned or has not responded adequately to prior treatment and is administered under specialist oncology care. In addition to its approved indication in AML, enasidenib mesylate is also being studied for potential use in other cancer types.
Mechanistically, enasidenib mesylate works by selectively inhibiting the abnormal IDH2 enzyme produced by the mutated gene. This inhibition helps reduce the production of oncometabolites that interfere with normal blood cell differentiation. Rather than directly killing cancer cells, the drug promotes the maturation of malignant cells into more normal forms, thereby slowing disease progression.
Enasidenib mesylate is classified as an enzyme inhibitor and is available as an oral tablet for once-daily administration. Commonly reported side effects include nausea, vomiting, diarrhea, reduced appetite, and elevated bilirubin levels. Due to potential risks to fetal and infant development, its use is not recommended during pregnancy or breastfeeding. Careful patient monitoring is essential throughout treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing